Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Weight loss has been shown to result in improvements in many comorbidities associated with obesity and T2D
Recent studies suggest the answer may be yes
Lilly and Novo Nordisk, which makes rival weight-loss drugs, struck deals with several telehealth companies in what they described as an effort to transition patients who were on compounded versions of their drugs to the name-brand version
Standard GLP-1 eligibility thresholds - based on the FDA-approved drug labeling for Wegovy and Zepbound, which guides how clinicians think about the category - generally include a BMI of 30 or higher (obese), or a BMI of 27 or higher with at least one weight-related comorbidity such as high blood pressure, high cholesterol, or type 2 diabetes
Patients who primarily want medication access sometimes feel that the program components add cost without proportional value
What they really mean is splitting their dose
